Abstract Number: 507 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Improves Left Ventricular Mass and Cardiac Output in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatologists need to develop primary prevention strategies for cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients. We reported tofacitinib (Tofa) plus methotrexate improved left…Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…Abstract Number: 1571 • 2016 ACR/ARHP Annual Meeting
Altered Bioenergetics, Mitochondrial Function and Pro-Inflammatory Pathways in RA Synovium in Response to Tofacitinib
Background/Purpose: Rheumatoid arthritis (RA) is a chronic joint disease, characterised by synovial inflammation and destruction of articular cartilage/bone. The Janus-Kinase and Signal Transducer and Activator…Abstract Number: 1608 • 2016 ACR/ARHP Annual Meeting
Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Treatment guidelines recommend targeting remission or low disease activity (LDA), herein…Abstract Number: 1637 • 2016 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib in Rheumatoid Arthritis: Data from the Swiss Clinical Quality Management RA Registry
Background/Purpose: The oral Janus kinase inhibitor Tofacitinib (Tofa) has been licensed in Switzerland 2013 for the treatment of patients with moderate to severe rheumatoid arthritis…Abstract Number: 1643 • 2016 ACR/ARHP Annual Meeting
Tofacitinib: Treatment Outcomes in Seropositive Versus Seronegative Patients in a Phase 3 RA Population
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This study examined response to treatment with tofacitinib 5 mg or 10…Abstract Number: 2580 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular prevention in RA. Tofacitinib (Tofa) could possibly…Abstract Number: 2593 • 2016 ACR/ARHP Annual Meeting
The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Background/Purpose: To analyze the effects of therapy with tofacitinib (Tofa), a Janus kinase inhibitor on the bone mineral density (BMD) of the lumbar spine and…Abstract Number: 2600 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Background/Purpose: Disease activity is the main risk factor for developing lymphoma in patients with rheumatoid arthritis (RA). However, the impact of immunosuppressive drugs remains an…Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…Abstract Number: 1643 • 2015 ACR/ARHP Annual Meeting
Modified-Release Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-Release Tofacitinib and Impact of Food
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation has been designed to enable once daily (QD)…Abstract Number: 2706 • 2015 ACR/ARHP Annual Meeting
3D Location of Erosions in an Early Rheumatoid Arthritis Population: An MRI Study Using Statistical Shape Models with Implications for Pathogenesis
Background/Purpose: Concepts of erosion pathogenesis in rheumatoid arthritis (RA) have been based on radiographs, although MR images are much better able to visualise erosions. Statistical…Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…Abstract Number: 2755 • 2015 ACR/ARHP Annual Meeting
Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation to provide a once-daily (QD) dosing alternative to…